ProCE Banner Activity

Slides: INTEGRATE IIa: Randomised double-blind Phase III  study of regorafenib versus placebo in refractory  advanced Gastro-Oesophageal Cancer (AGOC).

Slideset

Nick Pavlakis, MD discusses "INTEGRATE IIa: Randomised double-blind Phase III study of regorafenib versus placebo in refractory advanced Gastro-Oesophageal Cancer (AGOC)." in this virtual poster presentation.

Released: January 25, 2023

Expiration: January 24, 2024

Faculty

Nick Pavlakis

Nick Pavlakis, PhD, MBBS, FRACP

Medical Oncologist
Professor of Medicine
University of Sydney